Autoantibody to SPP1 was obvious to distinguish patients with ESCC from NC with the AUCs of 0.653 and 0.739 in discovery and validation group respectively, suggesting that serum anti-SPP1 autoantibody had potential significance to be a novel biomarker for ESCC detection. This evidence concerns the gene SPP1 and esophageal squamous cell carcinoma.